Sustained Viral Response Rate in 100 Subjects With Cirrhosis Due to Hepatitis C Treated With 12 Weeks of Sofosbuvir, Daclatasvir and Ribavirin
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2016
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms SD100
- 04 Sep 2016 Status changed from active, no longer recruiting to completed.
- 21 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Apr 2016.
- 28 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.